Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy ...

Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.

Wondering whether Madrigal Pharmaceuticals might be undervalued or perhaps riding a little too high? You are not alone, as many investors are digging into its numbers to decide if there is real value ...

Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH. The new patent extends Aramchol's patent ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

The average one-year price target for Madrigal Pharmaceuticals (NasdaqGS:MDGL) has been revised to $562.78 / share. This is an increase of 10.39% from the prior estimate of $509.81 dated November 7, ...

Investing.com - Truist Securities has raised its price target on Madrigal Pharmaceuticals (NASDAQ:MDGL) to $640.00 from $580.00 while maintaining a Buy rating on the stock. This target aligns with ...

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...